Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – December 9, 2020 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***For all DUR Board members, College of Pharmacy presenters, and any speakers who sign up in advance for public comment, this meeting will be held in person at OHCA (see address above). In response to COVID-19, masks, social distancing, and temperature checks will be required for all in person attendees. For additional information on OHCA's COVID-19 precautions and protocols for admittance into the Agency, please go to http://www.okhca.org.***

All non-speaking attendees are encouraged to join this meeting via Zoom access. The Zoom access will be set up in listen-only mode with no voting, speaking, or chat box privileges; however, the Zoom access will allow for viewing of the presentation slides during the meeting.

Viewing Access Only:

Register for the meeting by clicking on "Join Meeting as an Attendee" at:
https://okhca.zoom.us/s/99321236734?pwd=clB4STJmSlBVZklZeDRIVmM3OWozdz09

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Theresa Garton –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Public Access to Meeting via Zoom:

Register for the meeting by clicking on "Join Meeting as an Attendee" at:
https://okhca.zoom.us/s/99321236734?pwd=clB4STJmSlBVZklZeDRIVmM3OWozdz09

Or join by phone:
Dial: +1-669-900-6833 or +1-253-215-8782
Webinar ID: 993 2123 6734

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to *DURPublicComment@okhca.org*. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- For the December 2020 DUR Board meeting, any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see address above). Public comment through the OHCA Webinar will not be allowed for the December 2020 DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. November 4, 2020 DUR Minutes – Vote
B. November 4, 2020 DUR Recommendations Memorandum
C. Correspondence

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

4. Maintenance Drug List – See Appendix B

A. Introduction
B. SoonerCare Maintenance Drug List

Items to be presented by Dr. Ha, Dr. Travers, Dr. Muchmore, Chairman:

5. Update on Medication Coverage Authorization Unit/Pediatric Antipsychotic Monitoring Program Update – See Appendix C

A. Pharmacy Helpdesk Activity for November 2020
B. Medication Coverage Activity for November 2020
C. Pediatric Antipsychotic Monitoring Program Update

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize AirDuo® Digihaler® (Fluticasone Propionate/Salmeterol), ArmonAir® Digihaler® (Fluticasone Propionate), and Breztri Aerosphere™ (Budesonide/Glycopyrrolate/Formoterol Fumarate) – See Appendix D

A. New U.S. Food and Drug Administration (FDA) Approval(s)
B. New FDA Expanded Indication(s) and/or Formulation(s)
C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Blenrep (Belantamab Mafodotin-blmf), Darzalex® (Daratumumab), Darzalex Faspro™ (Daratumumab/Hyaluronidase-fihj), Empliciti® (Elotuzumab), Hemady™ (Dexamethasone 20mg Tablet), Ninlaro® (Ixazomib), Sarclisa® (Isatuximab-irfc), and Xpovio® (Selinexor) – See Appendix E

A. U.S. Food and Drug Administration (FDA) Approval(s) and Indication(s)
B. Product Summaries
C. Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Lenvima® (Lenvatinib) – See Appendix F

A. Lenvima® (Lenvatinib) Product Summary
B. Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

9. Action Item – Annual Review of Skin Cancer Medications – See Appendix G

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Skin Cancer Medications
D. Prior Authorization of Skin Cancer Medications
E. Market News and Updates
F. Recommendations
G. Utilization Details of Skin Cancer Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

10. Action Item – Annual Review of Antidepressants – See Appendix H

A. Current Prior Authorization Criteria
B. Utilization of Antidepressants
C. Prior Authorization of Antidepressants
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Antidepressants

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Abrilada™ (Adalimumab-afzb), Avsola™ (Infliximab-axxq), and Hulio® (Adalimumab-fkjp) – See Appendix I

A. Current Prior Authorization Criteria
B. Utilization of Targeted Immunomodulator Agents
C. Prior Authorization of Targeted Immunomodulator Agents
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

12. Annual Review of Soliris® (Eculizumab) and Ultomiris® (Ravulizumab-cwvz) and 30-Day Notice to Prior Authorize Enspryng™ (Satralizumab-mwge) and Uplizna™ (Inebilizumab-cdon) – See Appendix J

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Soliris® (Eculizumab) and Ultomiris® (Ravulizumab-cwvz)
D. Prior Authorization of Soliris® (Eculizumab) and Ultomiris® (Ravulizumab-cwvz)
E. Market News and Updates
F. Enspryng™ (Satralizumab-mwge) Product Summary
G. Uplizna™ (Inebilizumab-cdon) Product Summary
H. College of Pharmacy Recommendations
I. Utilization Details of Soliris® (Eculizumab) and Ultomiris® (Ravulizumab-cwvz)

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

13. Annual Review of Ulcerative Colitis (UC) and Crohn's Disease Medications and 30-Day Notice to Prior Authorize Ortikos™ [Budesonide Extended-Release (ER) Capsule] – See Appendix K

A. Current Prior Authorization Criteria

B. Utilization of UC and Crohn's Disease Medications
C. Prior Authorization of UC and Crohn's Disease Medications
D. Market News and Updates
E. Ortikos™ (Budesonide ER Capsule) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of UC and Crohn's Disease Medications

Items to be presented by Dr. Daniel, Dr. Muchmore, Chairman:

14. Annual Review of Constipation and Diarrhea Medications and 30-Day Notice to Prior Authorize Pizensy™ (Lactitol) – See Appendix L

A. Current Prior Authorization Criteria
B. Utilization of Constipation and Diarrhea Medications
C. Prior Authorization of Constipation and Diarrhea Medications
D. Market News and Updates
E. Pizensy™ (Lactitol) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Constipation Medications
H. Utilization Details of Diarrhea Medications

Non-Presentation/Questions Only:

15. Annual Review of Thrombocytopenia Medications – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of Thrombocytopenia Medications
C. Prior Authorization of Thrombocytopenia Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Thrombocytopenia Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)
No live meeting scheduled for January 2021. January 2021 will be a packet only meeting.

A. Antiviral Medications
B. Glaucoma Medications
C. Gonadotropin-Releasing Hormone (GnRH) Medications
D. Hyperlipidemia Medications
**Future product and class reviews subject to change.*

18. Adjournment